Join the club for FREE to access the whole archive and other member benefits.

Cytox

Company developing blood tests for risk assessment for Alzheimer's disease and dementia

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.

Visit website: http://www.cytoxgroup.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.